We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Acquisition Includes Radiation Simulation Software for Radiotherapy Applications

By MedImaging International staff writers
Posted on 12 Aug 2014
Print article
Varian Medical Systems, Inc. (Palo Alto, CA, USA) has acquired certain assets of Transpire, Inc. (Gig Harbor, WA, USA) including the Acuros dose calculation software, which has been incorporated into Varian’s BrachyVision and Eclipse treatment planning software systems. The acquisition closed at the end of July 2014.

“Acuros software makes it possible to implement highly precise forms of treatment in heterogeneous tissues such as the lung—something other algorithms do not do as well,” said Jeff Amacker, Varian’s senior director of clinical solutions. “Acuros can accomplish this in a workable timeframe, compared with more cumbersome Monte Carlo approaches that are just not used because they take too long.”

“Varian and Transpire have enjoyed an OEM [original equipment manufacturer] relationship since 2008, when we first incorporated the Acuros algorithm into our systems for planning and delivering high-precision radiotherapy for the treatment of cancer,” said Kolleen Kennedy, president of Varian’s oncology systems business. “This acquisition will enable us to continue leveraging the Acuros solution for use in proton therapy, and for improving our image guidance tools on other Varian treatment systems. We look forward to working directly with Transpire's accomplished team of engineers and scientists, who have now joined the Varian team, to further refine and enhance our treatment planning software systems.”

The acquisition also entails Transpire’s Attila software, which is in use worldwide in a diverse range of industries where radiation effects play an integral role in product performance, safety, and effectiveness. “We plan to integrate Attila software with our products for security and inspection applications,” stated Sunny Sanyal, president of Varian’s imaging components businesses. “It will enable us to provide comprehensive solutions for customers that integrate Varian’s high-energy X-ray technology into systems for cargo screening, industrial inspection and nondestructive testing.”

Varian will continue developing the Acuros and Attila software products with the Transpire team. “We are very pleased that the Transpire team has joined our organization,” said Dow Wilson, Varian CEO. “This is a world-class group of scientists with deep experience at the intersection of nuclear engineering and software development. We believe that they will help us continue fulfilling our mission of providing customers with empowering software solutions.”

Varian Medical Systems is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy.


Related Links:

Varian Medical Systems
Transpire


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Mobile X-Ray Barrier
Lead Acrylic Mobile X-Ray Barriers
Portable X-Ray Unit
AJEX240H
New
Enterprise Imaging & Reporting Solution
Syngo Carbon

Print article
Radcal

Channels

MRI

view channel
Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)

Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients

Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read more

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.